TREM2 function in glioblastoma immune microenvironment: Can we distinguish reality from illusion?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. TREM2 in glioma: Reprogramming the immune microenvironment from mechanistic understanding to clinical translation (Review).Molecular medicine reports · 2026
   Review
2. Lipid-Metabolically Active TREM2Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
   Article
3. Novel cuprotosis-related gene signature: a prognostic indicator and regulator of the glioma immune microenvironment.Translational cancer research · 2024
   Article

Corrections and comments

• Comment on
  TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas.2024
• Comment on
  Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma.2024

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as